STOCK TITAN
  1. Home
  2. News
  3. VYGR

Voyager Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation platform technologies, today announced that it will participate in the following upcoming virtual investor conferences.

  • Wedbush PacGrow Healthcare Conference, panel discussion, August 11, 2021, 8:35 AM ET.
  • Canaccord Genuity Growth Conference, fireside chat, August 12, 2021, 10:30-10:55 AM ET.

The sessions may be accessed from the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com. Replays of the webcasts will be archived on the Company's website for at least 30 days.

About Voyager Therapeutics
Voyager Therapeutics (Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock the potential of the technology to treat devastating diseases. Proprietary capsids born from the Company’s TRACER™ screening platform are powering a rich early-stage pipeline of new and second-generation programs and may elevate the field to overcome the limitations of conventional gene therapy vectors across neurological disorders and other therapeutic areas.

voyagertherapeutics.com LinkedIn Twitter

Investor Inquiries:        
investors@voyagertherapeutics.com

Media Inquiries:        
Scott Santiamo
ssantiamo@voyagertherapeutics.com


Stock VYGR logo
Voyager Therapeutics Inc

NASDAQ:VYGR

VYGR Rankings

#3111 Ranked by Market Cap
#801 Ranked by Stock Gains
N/A Ranked by Dividends

VYGR Latest News

Apr 16, 2024
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
Mar 26, 2024
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 13, 2024
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
Feb 28, 2024
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
Feb 26, 2024
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

VYGR Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
US
Cambridge

About VYGR

voyager therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (cns). voyager is committed to advancing the field of aav (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. the company’s initial pipeline is focused on cns diseases in dire need of effective new therapies, including parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (als), and friedreich’s ataxia. founded by scientific and clinical leaders in the fields of aav gene therapy, expressed rna interference and neuroscience, voyager therapeutics was launched in 2014 with funding from leading life sciences investor third rock ventures and is headquartered in cambridge, mass. for more information, please visit www.voyagertherapeutics.com.